Pancreatic ductal adenocarcinoma—a new hope?

Pancreatic ductal adenocarcinoma (PDAC) is typically an advanced and aggressive disease and improving outcomes for patients with this cancer remains a significant challenge. Few patients present with resectable disease, and recurrence rates after surgery remain high (70–80%). Modern chemotherapy (CMT) and radiotherapy (RT) regimens have made small improvements to survival and many of these treatments confer little benefit whilst delivering unpleasant side-effects. Alternative treatment modalities, such as electroporation, are under development and pancreatic cancer still awaits a “game-changer”.